Your session is about to expire
← Back to Search
Dostarlimab for Advanced Cancer (GARNET Trial)
GARNET Trial Summary
This trial is testing a new drug for people with advanced solid tumors who have limited available treatment options. The study will evaluate the safety and effectiveness of the drug.
GARNET Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowGARNET Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 18 Patients • NCT04409002GARNET Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My condition worsened after platinum-based chemotherapy.I've had up to 2 cancer treatments for my advanced disease, not counting hormone therapy.My tumor's MMR/MSI status was checked and is eligible for the trial.My cancer has returned and is advanced.I have an EGFR mutation and have been treated with both chemotherapy and an EGFR inhibitor.I have been treated with a PARP inhibitor before.My NSCLC worsened after platinum-based chemotherapy.I agree to use effective birth control from the start of the study until 150 days after the last treatment.I have been treated with drugs targeting the PD-1 or PD-L1/L2 pathways.I have untreated brain metastases or cancer in the lining of my brain.I have a specific type of tumor that is not responding to treatment and have no other options.I have had 1 to 3 treatments for advanced ovarian cancer, not counting bevacizumab maintenance.My cancer has returned or worsened after treatment, or I cannot tolerate the treatment.I have 2 scans showing my cancer has grown after my last cancer treatment.I have been diagnosed with HIV.I have recovered from previous treatment side effects and haven't had blood transfusions or certain medications in the last 3 weeks.I still have significant side effects from a recent major surgery.I have not received a live vaccine in the last 14 days.I have a weakened immune system.I have ALK-positive cancer and have been treated with both chemotherapy and an ALK inhibitor.My scans show a measurable tumor, and I will have them reviewed before starting dostarlimab.I have stored tumor samples that are preserved in a specific way.My organs are functioning well.I have been treated with platinum, taxane, and bevacizumab for my cancer.I am not pregnant or cannot become pregnant.I cannot become pregnant due to age, surgery, or menopause.I have active hepatitis B or C.I have a history of interstitial lung disease.I can perform all self-care but may not be able to do heavy physical work.My cancer did not worsen within 3 months after starting first-line platinum therapy.I haven't had active cancer treatment in the last 2 years, except for certain skin cancers or in situ cervical cancer.I have a serious health condition that is not well-controlled.I have an immune system disorder or have been on steroids or other immune-weakening medicines recently.My cancer returned within 6 months after my last platinum-based treatment.My NSCLC worsened after platinum-based chemotherapy.My condition worsened after platinum-based chemotherapy.I have an autoimmune disease treated within the last 2 years.My cancer has returned and is advanced.I've had cancer treatment within the last 21 days or less than 5 half-lives of the treatment.My tumor's MMR/MSI status was checked with a certified test.I have recurrent ovarian, fallopian tube, or peritoneal cancer with at least one measurable lesion.You must have at least one visible abnormality that can be measured on a medical scan, which will be reviewed by a radiologist.My cancer is endometrial, but not a sarcoma type.a. Part 1: You have a type of cancer that has come back and is advanced.
b. Part 2A: You have a type of cancer that has come back and is advanced. Specifically, for Cohort A1, you have a type of endometrial cancer that has specific genetic markers called dMMR or MSI-H.I have two scans showing my cancer has grown after my last cancer treatment.You have been part of another research study and used an experimental drug or device within the last 4 weeks.My advanced cancer has a measurable tumor and is confirmed by tests.My endometrial cancer is MMR-proficient/MSS.My endometrial cancer is either MSI-H/dMMR or MSS/MMR-proficient.I am 18 years old or older.I have a harmful BRCA1 or BRCA2 gene mutation.
- Group 1: Part 2B: Cohort A2 MMR-proficient/MSS endometrial cancer
- Group 2: Part 1: Participants receiving dostarlimab
- Group 3: Part 2A: Participants receiving dostarlimab
- Group 4: Part 2B: Cohort A1 dMMR/MSI-H endometrial cancer
- Group 5: Part 2B: Cohort E NSCLC
- Group 6: Part 2B:Cohort F non-endometrial dMMR/MSI-H & POLE-Mut cancers
- Group 7: Part 2B: Cohort G PROC without known BRCA
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What previous investigations have been undertaken with Dostarlimab?
"Dostarlimab was first examined at City of Hope in 2010, and since then 1 trial has been finalized. As for now, 40 active studies are being conducted, primarily based out of Kansas City."
Could you share the locations where this experiment is currently being conducted?
"Presently, 50 medical clinics across the United States are enrolling for this clinical trial. It is advisable to choose a clinic in Kansas City, Augusta or Scarborough to minimize travel requirements should you elect to join."
Are there any vacancies for this research project?
"Affirmative. Data hosted on clinicaltrials.gov is indicative of this study's continued recruitment efforts; the trial was initially posted in March 2016 and most recently modified November 2022, with an aim to assemble 740 patients across 50 sites nationwide."
Has Dostarlimab been given the green light by the Food and Drug Administration?
"Our team at Power has assigned Dostarlimab a safety rating of 1 since this is an early stage trial, with minimal evidence to validate its efficacy and security."
How many participants have signed up to take part in this trial?
"Affirmative. Reports hosted on clinicaltrials.gov demonstrate that this medical investigation, first posted on March 7th 2016, is currently recruiting participants. The research requires the recruitment of 740 subjects from 50 different sites."
What is the ultimate goal of this research project?
"This trial will be ongoing for up to two years and aims to quantify the number of patients experiencing adverse events. Secondary objectives include determining serum levels of dostarlimab, recording progression-free survival times, and calculating disease control rate in Cohort A1 according to RECIST v1.1 criteria."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- GSK Investigational Site: < 48 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger